Seminars in Hematology
Volume 43, Issue 4 , Pages 205-206 , October 2006

Treatment of Diffuse Large B-Cell Lymphomas

References 

  1. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–10066
  2. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood. 1998;92:1927–1932
  3. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242
  4. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier C, Grogan T, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339:21–26
  5. Haberman TM, Weller EA, Morrison VA, Cassileth PA, Cohn BB, Dakhil SR, et al. Phase III trial of rituximab-CHOP vs. CHOP with a second randomization to maintenance rituximab or observation in patients 60 years of age and older with diffuse large B cell lymphoma. Blood. 2003;102:6a
  6. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634–641

PII: S0037-1963(06)00155-7

doi: 10.1053/j.seminhematol.2006.07.007

Seminars in Hematology
Volume 43, Issue 4 , Pages 205-206 , October 2006

Article Tools